首页> 外文期刊>Biochemistry >Sulbactam Forms Only Minimal Amounts of Irreversible Acrylate-Enzyme with SHV-1 beta-Lactamase
【24h】

Sulbactam Forms Only Minimal Amounts of Irreversible Acrylate-Enzyme with SHV-1 beta-Lactamase

机译:Sulbactam与SHV-1β-内酰胺酶仅形成最小量的不可逆丙烯酸酯酶

获取原文
获取原文并翻译 | 示例
           

摘要

Sulbactam is a mechanism-based inhibitor of beta-lactamase enzymes used in clinical practice. It undergoes a complex series of chemical reactions in the active site that have been studied extensively in the past three decades. However, the actual species that gives rise to inhibition in a clinical setting has not been established. Recent studies by our group, using Raman microscopy and X-ray crystallography, have found that large quantities of enamine-based acyl-enzyme species are present within minutes in single crystals of SHV-1 beta-lactamases which can lead to significant inhibition. The enamines are formed by breakdown of the cyclic beta-lactam structures with further transformations leading to imine formation and subsequent isomerization to cis and/or trans enamines. Another favored form of inhibition arises from attack on the imine by a second nucleophilic amino acid side chain, e.g., from serine 130, to form a cross-linked species in the active site that can degrade to an acrylate-like species irreversibly bound to the enzyme. Thus, the imine is at a branch point on the reaction pathway. Using sulbactam and 6,6-dideuterated sulbactam we follow these alternate paths in WT and El66A SHV-1 beta-lactamase by means of Raman microscopic studies on single enzyme crystals. For the unlabeled sulbactam, the Raman data show the presence of an acrylate-like species, probably 3-serine acrylate, several hours after the reaction is started in the crystal. However, for the 6,6-dideutero analogue the acrylate signature appears on the time scale of minutes. The Raman signatures, principally an intense feature near 1530 cm~(-1), are assigned based on quantum mechanical calculations on model compounds that mimic acrylate species in the active site. The different time scales observed for acrylate-like product formation are ascribed to different rates of reaction involving the imine intermediate. It is proposed that for the unsubstituted sulbactam the conversion from imine to enamine, which involves breaking a C-H bond, is aided by quantum mechanical tunneling. For the 6,6-dideutero-sulbactam the same step involves breaking a C-D bond, which has little or no assistance from tunneling. Consequently the conversion to enamines is slower, and a higher population of imine results, presenting the opportunity for the competing reaction with the second nucleophile, serine 130 being the prime candidate. The hydrolysis of the resulting cross-linked intermediate leads to the observed rapid buildup of the acrylate product in the Raman spectra from the dideutero analogue. The protocol used here, essentially running the reactions with the two forms of sulbactam in parallel, provides an element of control and enables us to conclude that, for the unsubstituted sulbactam, the formation of the cross-linked intermediate and the final irreversible acrylate product is not a significant route to inhibition of SHV-1.
机译:舒巴坦是临床实践中使用的基于机制的β-内酰胺酶抑制剂。在过去的三十年中,它在活性位点经历了一系列复杂的化学反应,对此进行了广泛的研究。然而,尚未建立在临床环境中引起抑制的实际物种。我们小组最近使用拉曼显微镜和X射线晶体学进行的研究发现,数分钟之内SHV-1β-内酰胺酶单晶中就会存在大量基于烯胺的酰基酶,这可能导致明显的抑制作用。烯胺是通过环状β-内酰胺结构的分解并进一步转化而形成的,这些转化导致亚胺的形成以及随后的异构化为顺式和/或反式烯胺。另一种有利的抑制形式是由第二个亲核氨基酸侧链(例如来自丝氨酸130)攻击亚胺,从而在活性位点形成交联物种,该交联物种可降解为不可逆地结合于其上的丙烯酸酯样物种。酶。因此,亚胺在反应路径上的分支点上。使用舒巴坦和6,6-氘代舒巴坦,我们通过对单个酶晶体的拉曼显微镜研究,在WT和El66A SHV-1β-内酰胺酶中遵循了这些替代途径。对于未标记的舒巴坦,拉曼数据显示了在晶体中开始反应数小时后,丙烯酸酯样物质(可能是3-丝氨酸丙烯酸酯)的存在。然而,对于6,6-二氟代硝基类似物,丙烯酸酯标记出现在分钟的时间刻度上。拉曼签名主要是在1530 cm〜(-1)附近的一个强烈特征,是基于对模拟活性部位中丙烯酸酯类物质的模型化合物进行量子力学计算而得出的。对于丙烯酸酯样产物形成观察到的不同时间尺度归因于涉及亚胺中间体的不同反应速率。提出了对于未取代的舒巴坦,从亚胺到烯胺的转化涉及断裂C-H键,这是通过量子机械隧穿来辅助的。对于6,6- dideutero-sulbactam,相同的步骤涉及破坏C-D键,这种键很少或没有隧道帮助。因此,向烯胺的转化较慢,并且产生了更多的亚胺,为与第二亲核试剂(丝氨酸130为主要候选物)的竞争反应提供了机会。所得交联的中间体的水解导致在拉曼光谱中从双歧类似物快速观察到丙烯酸酯产物的堆积。此处使用的方案基本上与两种形式的舒巴坦并行进行反应,提供了控制因素,使我们可以得出结论,对于未取代的舒巴坦,交联中间体和最终不可逆丙烯酸酯产物的形成是不是抑制SHV-1的重要途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号